Alexander SH, Misty MA, Mathias Rask-Andersen, Helgi BS, David EG. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. (2017) 12:829-842
Alkanfari I, Gupta K, Jahan T, Ali H. Naturally Occurring Missense MRGPRX2 Variants Display Loss of Function Phenotype for Mast Cell Degranulation in Response to SP, Hemokinin-1, Human β-Defensin-3, and Icatibant. J. Immunol. (2018) 201: 343-349
Azimi E, Reddy VB, Shade KC, Anthony RM, Talbot S, Pereira PJS, Lerner EA. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight (2016) 1: e89362
Azzolina A, Guarneri P, Lampiasi N. Involvement of p38 and JNK MAPKs pathways in SP-induced production of TNF-alpha by peritoneal MCs. Cytokine (2002) 18: 72-80
Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. Dis. (1989) 139: 806-817
Benyon RC, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin MCs activated by IgE-dependent and non-immunological stimuli. Br. J. Pharmacol. (1989) 97:
898-904
Bienenstock J, MacQueen G, Sestini P, Marshall JS, Stead RH, Perdue MH. Mast cell/nerve interactions in vitro and in vivo. Am. Rev. Respir. Dis. (1991) 143: S55-58
~ 78 ~
Bjellqvist B, Hughes GJ, Pasquali C, Paquet N, Ravier F, Sanchez JC, Frutiger S, Hochstrasser D. The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences. Electrophoresis (1993) 10: 1023-1031
Bjorling DE, Saban MR, Zine MJ, Haak-Frendscho M, Graziano FM, Saban R. In vitro passive sensitization of guinea pig, rhesus monkey and human bladders as a model of noninfectious cystitis.
J. Urol. (1994) 152: 1603-1608
Boix E, Leonidas DD, Nikolovski Z, Nogués MV, Cuchillo CM, Acharya KR. Crystal structure of eosinophil cationic protein at 2.4 A resolution. Biochemistry (1999) 38: 16794-16801
Caughey GH. Of mites and men: trypsin-like proteases in the lungs. Am. J. Respir. Cell Mol. Biol.
(1997) 16: 621-628
Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM. Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin. Immunol. Immunopathol. (1996) 81:68-73
Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell (2001) 106: 619–632
Elishmereni M, Bachelet I, Nissim Ben-Efraim AH, Mankuta D, Levi-Schaffer F. Interacting mast cells and eosinophils acquire an enhanced activation state in vitro. Allergy (2013) 68: 171-179
~ 79 ~
Han SK, Dong X, Hwang J, Zylka MJ, Anderson DJ, Simon MI. Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. Proc. Natl. Acad. Sci. USA 99 (2002) 14740– 14745
Fang Y, Kenakin T. Liu C. Editorial: Orphan GPCRs As Emerging Drug Targets. Front. Pharmacol.
(2015) 6: 295
Ferry X, Eichwald V, Daeffler L, Landry Y. Activation of betagamma subunits of G(i2) and G(i3) proteins by basic secretagogues induces exocytosis through phospholipase Cbeta and arachidonate release through phospholipase Cgamma in MCs. J. Immunol. (2001) 167: 4805-4813
Ferry X, Brehin S, Kamel R, Landry Y. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides (2002) 23: 1507–1515
Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet (1982) 2: 11-16
Foreman JC and Lichtenstein LM. Induction of histamine secretion by polycations. Biochim. Biophys.
Acta. (1980) 629: 587-603
Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.
Mol. Pharmacol. (2003) 63: 1256–1272
~ 80 ~
Frigas E, Loegering DA, Solley GO, Farrow GM, Gleich GJ. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo. Clin. Proc. (1981) 56: 345-353
Fujisawa D, Kashiwakura J, Kita H, Kikukawa Y, Fujitani Y, Sasaki-Sakamoto T, Kuroda K, Nunomura S, Hayama K, Terui T, Ra C, Okayama Y. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J. Allergy Clin. Immunol.
(2014)134: 622-633
Furuta GT, Ackerman SJ, Lu L, Williams RE, Wershil BK. Stem cell factor influences mast cell mediator release in response to eosinophil-derived granule major basic protein. Blood (1998) 92:
1055-1061
Kamohara M, Matsuo A, Takasaki J, Kohda M, Matsumoto M, Matsumoto S, Soga T, Hiyama H, Kobori M, Katou M. Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. Biochem. Biophys. Res. Commun. (2005) 330: 1146–1152
Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology Am. Soc.
Hematol. Educ. Program. (2015) 2015: 92-97
Kimata M, Inagaki N, Kato T, Miura T, Serizawa I, Nagai H. Roles of mitogen-activated protein kinase pathways for mediator release from human cultured MCs. Biochem. Pharmacol. (2000) 60: 589-594
~ 81 ~
Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu. Rev.
Immunol. (1999) 17: 931–972.
Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J. Cell Sci. (2003) 116:
4867–4869
Kumagai Y and Akira S. Identification and functions of pattern-recognition receptors. J. Allergy Clin.
Immunol. (2010) 125:985-992
Lansu K, Karpiak J, Liu J, Huang XP, McCorvy JD, Kroeze WK, Che T, Nagase H, Carroll FI, Jin J, Shoichet BK, Roth BL. In silico design of novel probes for the atypical opioid receptor MRGPRX2.
Nat. Chem. Biol. (2017) 13: 529-536
Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM. Purification and characterization of human skin MCs. Evidence for human mast cell heterogeneity. J. Immunol.
(1987) 139: 3062-3069
Lembo PMC, Grazzini E, Groblewski T, O’Donnell D, Roy M-O, Zhang J, Hoffert C, Cao J, Schmidt R, Pelletier M, Labarre M, Gosselin M, Fortin Y, Banville D, Shen SH, Strom P, Payza K, Dray A, Walker P, Ahmad S. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat. Neurosci. (2002) 5: 201–209
Levi-Schaffer F, Temkin V, Malamud V, S Feld, Zilberman Y. Mast cells enhance eosinophil survival in vitro, role of TNF-alpha and granulocyte-macrophage colony-stimulating factor. J. Immunol. (1998)
~ 82 ~
160: 5554-5562
Ma AWS, Pawagi AB, Wells JW. Heterooligomers of the muscarinic receptor and G proteins purified from porcine atria. Biochem. Biophys. Res. Commun. (2008) 374: 128-133
Marshall JS and Bienenstock J. Mast cells, Springer Semin. Immunopathol. (1990) 12: 191–202
McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, Dong X. Identification of a MC specific receptor crucial for pseudo-allergic drug reactions. Nature (2015) 519: 237-241
Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol. Rev. (1997) 77: 1033–1079
Minai-Fleminger Y, Elishmereni M, Vita F, Soranzo MR. Mankuta D, Zabucchi G, Levi-Schaffer F.
Ultrastructural evidence for human mast cell-eosinophil interactions in vitro. Cell Tissue Res. (2010) 341: 405-415
Moon TC, Lee E, Baek S-H, Murakami M, Kudo I, Kim NS, Lee JM, Min H-K, Kambe N, Chang HW. Degranulation and cytokine expression in human cord blood-derived mast cells cultured in serum-free medium with recombinant human stem cell factor. Mol. Cell (2003) 16: 154–160
Mousli M, Bronner C, Bueb JL, Tschirhart E, Gies JP, Landry Y. Activation of rat peritoneal MCs by SP and mastoparan. J. Pharmacol. Exp. Ther. (1989) 250: 329-335
Mousli M, Bronner C, Bockaert J, Rouot B, Landry Y. Interaction of SP, compound 48/80 and
~ 83 ~
mastoparan with the alpha-subunit C-terminus of G protein. Immunol. Lett. (1990) 25: 355-357
Murthy KS, Zhou H, Grider JR, Brautigan DL, Eto M, Makhlouf GM. Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway. Biochem. J. (2003) 374: 145-155
Nadler MJ, Matthews SA, Turner H, Kinet JP. Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function. Adv. Immunol. (2001) 76: 325–
355
Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, Gastaminza G.
MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia.
Sci. Rep. (2018) 8:11628
Nunn C, Langenegger D, Hurth K, Schmidt K, Fehlmann D, Hoyer D. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists. Eur. J. Pharmacol. (2003) 465:211-218
O'Donnell MC, Ackerman SJ, Gleich GJ, Thomas LL. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J. Exp. Med. (1993) 157: 1981-1991
Offermanns S, Wieland T, Homann D, Sandmann J, Bombien E, Spicher K, Schultz G, Jakobs KH.
~ 84 ~
Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11.
Mol. Pharmacol. (1994) 45: 890-898
Ogawa K, Nabe T, Yamamura H, Kohno S. Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats. Eur. J. Pharmacol. (1999) 374: 285-291
Okabe T, Hide M, Koro O, Yamamoto S. SP induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. Eur. J. Pharmacol. (2000) 398: 309-315
Okayama Y, el-Lati SG, Leiferman KM, Church MK. Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells. J. Allergy Clin. Immunol. (1994) 93: 900-909
Ottosson A and Edvinsson L. Release of histamine from dural MCs by SP and calcitonin gene-related peptide. Cephalalgia (1997) 17: 166-174
Pang X, Marchand J, Sant GR, Kream RM, Theoharides TC. Increased number of SP positive nerve fibres in interstitial cystitis. Br. J. Urol. (1995) 75: 744-750
Patella V, de Crescenzo G, Marinò I, Genovese A, Gleich GJ, Marone G. Eosinophil granule proteins activate human heart mast cells. J. Immunol. (1996) 157: 1219-1225
Piliponsky AM, Pickholtz D, Gleich GJ, Levi-Schaffer F. Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic
~ 85 ~
reactions. J. Allergy Clin. Immunol. (2001) 107: 993-1000
Piliponsky AM, Gleich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood (2003) 101: 1898-1904
Piper AR, Pier GP, Hadas P, Francesca LS, Bruce SB. Human eosinophils and mast cells: birds of a feather flock together. Immunol. Rev. (2018) 282: 151–167
Plager DA, Loegering DA, Weiler DA, Checkel JL, Wagner JM, Clarke NJ, Naylor S, Page SM, Thomas LL, Akerblom I, Cocks B, Stuart S, Gleich GJ. A Novel and Highly Divergent Homolog of Human Eosinophil Granule Major Basic Protein. J. Biol. Chem. (1999) 274: 14464-14473
Regoli D, Dion S, Rhaleb NE, Rouissi N, Tousignant C, Jukic D, D'Orleans-Juste P, Drapeau G.
Selective agonists for receptors of substance P and related neurokinins. Biopolymers (1989) 28:81-90
Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. (2003) 27: 8 44400–44404
Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature (2009) 459: 356–363
Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J. Immunol. (1987) 138: 2611-2615
~ 86 ~
Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J. Clin. Invest. (1989) 83: 1551-1555
Schwartz LB. Mast cells: function and contents. Curr. Opin. Immunol. (1994) 6: 91–97
Shefler I, Seger R, Sagi-Eisenberg R. Gi-mediated activation of mitogen-activated protein kinase (MAPK) pathway by receptor mimetic basic secretagogues of connective tissue-type MCs: bifurcation of arachidonic acid-induced release upstream of MAPK. J. Pharmacol. Exp. Ther. (1999) 289: 1654-1661
Shefler I and Sagi-Eisenberg R. Gi-mediated activation of the p42/p44 mitogen-activated protein kinases by receptor mimetic basic secretagogues is abrogated by inhibitors of endocytosis. Int.
Immunopharmacol. (2002) 2: 711-720
Siraganian RP. Mast cell signal transduction from the high-affinity IgE receptor. Curr. Opin. Immunol.
(2003) 15: 639–646
Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J. Intestinal mucosal MCs in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc. Natl.
Acad. Sci. U. S. A. (1987) 84: 2975-2979
Subramanian H, Gupta K, Guo Q, Price R, Ali H. Mas-related gene X2 (MrgX2) is a novel G
protein-~ 87 protein-~
coupled receptor for the antimicrobial peptide LL-37 in human MCs: resistance to receptor phosphorylation, desensitization, and internalization. J. Biol. Chem. (2011) 286:44739-4449
Swaminathan GJ. Weaver AJ, Loegering DA, Checkel JL, Leonidas DD, Gleich GJ, Acharya KR.
Crystal structure of the eosinophil major basic protein at 1.8 A. An atypical lectin with a paradigm shift in specificity. J. Biol. Chem. (2001) 276: 26197-26203
Tang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta. Pharmacol. Sin. (2012) 33: 363-71
Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem. Biophys. Res. Commun. (2006) 349:1322-1328
Tatemoto K, Nozaki Y, Tsuda R, Kaneko S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T. Endogenous protein and enzyme fragments induce immunoglobulin E-independent activation of mast cells via a G protein-coupled receptor. MRGPRX2.
Scand. J. Immunol. (2018) 87: e12655
Temkin V, Kantor B, Weg V, Hartman ML, Levi-Schaffer F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J. Immunol. (2002) 169: 2662-2669
Theoharides TC and Cochrane DE. Critical role of MCs in inflammatory diseases and the effect of
~ 88 ~
acute stress. J. Neuroimmunol. (2004) 146: 1-12
Thomas LL, Kubo H, Loegering DJ, Spillard K, Weaver AJ, McCormick DJ, Weiler C, Gleich GJ.
Peptide-based analysis of amino acid sequences important to the biological activity of eosinophil granule major basic protein. Immunol. Lett. (2001) 78: 175-181
Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature (2013) 494: 185–194
Violin JD, Crombie AL, Soergel DG, Lark MW. Biased ligands at G-protein-coupled receptors:
promise and progress. Trends in Pharmacol. Sci. (2014) 35: 308-316
Wallengren J. Vasoactive peptides in the skin. J. Investig. Dermatol. Symp. Proc. (1997) 2: 49-55
Walls AF. Neutral proteases in asthma and rhinitis In: W.W. Busse, S.T. Holgate editors. Asthma and Rhinitis. 2nd Edition Boston, Blackwell, (2000); 968–998
Wassom DL, Loegering DA, Solley GO, Moore SB, Schooley RT. Fauci AS, Gleic GJ. Elevated serumlevels of the eosinophil granule major basic protein in patients with eosinophilia. J. Clin. Invest.
(1981) 67: 651-661
Yu Y, Zhang Y, Zhang Y, Lai Y, Chen W, Xiao Z, Zhang W, Jin M, Yu B. LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2. Int. Immunopharmacol. (2017) 49: 6-12
~ 89 ~
Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J. Immunol. (1984) 133: 2180-2185
Zylka MJ, Dong X, Southwell AL, Anderson DJ. Atypical expansion in mice of the sensory neuron-specific Mrg G proteincoupled receptor family. Proc. Natl. Acad. Sci. U. S. A. (2003) 100: 10043–
10048
~ 90 ~
Table 2の基となるデータ（その1）
A, ペプチドもしくは溶媒添加後の最大ratio値 B, ペプチドもしくは溶媒添加前のratio値
ratio値とは340 nmの励起光で励起した際の510 nmの蛍光強度と，波長380 nmの励起光により励起した際の510 nmの蛍光強度の比の値。
Δratioとはサンプル添加後の最大変化ratio値（A-B）。
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3563 0.3583 0.3659 0.3650 0.3584 0.3424 -0.0020 0.0009 0.0160 0.0050 0.0097
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SP刺激 CNT 0.4517 0.3483 0.4691 0.3537 0.4773 0.3560 0.1034 0.1154 0.1213 0.1134 0.0091 100.000 8.415 1.27 10 0.3679 0.3569 0.3600 0.3471 0.3806 0.3652 0.011 0.0129 0.0154 0.0131 0.0022 7.503 2.036
3 0.3963 0.3618 0.3869 0.3540 0.3803 0.3490 0.0345 0.0329 0.0313 0.0329 0.0016 25.769 1.476 1 0.4210 0.3550 0.4129 0.3430 0.4224 0.3591 0.066 0.0699 0.0633 0.0664 0.0033 56.673 3.061 0.3 0.4337 0.3401 0.4459 0.3557 0.4468 0.3618 0.0936 0.0902 0.085 0.0896 0.0043 78.075 3.996
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3504 0.3526 0.3444 0.3612 0.3518 0.3500 -0.0022 -0.0168 0.0018 -0.0057 0.0098
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SP刺激 CNT 0.5143 0.3452 0.4954 0.3507 0.5019 0.3457 0.1691 0.1447 0.1562 0.1567 0.0122 100.000 7.516 1.45 10 0.3659 0.3468 0.3627 0.3498 0.3666 0.3462 0.0191 0.0129 0.0204 0.0175 0.0040 14.286 2.468
3 0.3977 0.3467 0.4017 0.348 0.3927 0.3518 0.0510 0.0537 0.0409 0.0485 0.0067 33.415 4.155 1 0.4305 0.3406 0.4467 0.3553 0.4422 0.3565 0.0899 0.0914 0.0857 0.0890 0.0030 58.333 1.819 0.3 0.5109 0.344 0.4901 0.3458 0.4977 0.3583 0.1669 0.1443 0.1394 0.1502 0.0147 96.018 9.032
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3461 0.3466 0.3536 0.3544 0.3518 0.3532 -0.0005 -0.0008 -0.0014 -0.0009 0.0005
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SP刺激 CNT 0.4876 0.3362 0.4957 0.3465 0.4914 0.3357 0.1514 0.1492 0.1557 0.1521 0.0033 100.000 2.161 1.66 10 0.3588 0.3453 0.3625 0.3483 0.3461 0.3262 0.0135 0.0142 0.0199 0.0159 0.0035 10.959 2.294
3 0.3989 0.3367 0.3803 0.3335 0.3946 0.3418 0.0622 0.0468 0.0528 0.0539 0.0078 35.839 5.073 1 0.4291 0.33 0.4348 0.3407 0.4272 0.3400 0.0991 0.0941 0.0872 0.0935 0.0060 61.678 3.905 0.3 0.4859 0.3384 0.4981 0.3358 0.4796 0.3383 0.1475 0.1623 0.1413 0.1504 0.0108 98.867 7.052 compound 1のSP 10μM刺激の細胞内Ca2+濃度上昇阻害IC50値は異なる実験3回の平均として算出
平均値 標準偏差値
IC50値 1.5 μM 0.20
Δratio
1 2 3
Δratio
1 2 3 誘導比
(%)
10 μM SP刺激
＋compound 1 (μM )
Δratio
1 2 3
Δratio
1 2 3 誘導比
(%)
Δratio
1 2 3
10 μM SP刺激
＋compound 1 (μM )
Δratio
1 2 3 誘導比
(%) 10 μM SP刺激
＋compound 1 (μM )
~ 91 ~
Table 2の基となるデータ（その2）
A, ペプチドもしくは溶媒添加後の最大ratio値 B, ペプチドもしくは溶媒添加前のratio値
ratio値とは340 nmの励起光で励起した際の510 nmの蛍光強度と，波長380 nmの励起光により励起した際の510 nmの蛍光強度の比の値。
Δratioとはサンプル添加後の最大変化ratio値（A-B）。
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3703 0.3583 0.3671 0.365 0.3433 0.3424 0.0120 0.0021 0.0009 0.0050 0.0061
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SP刺激 CNT 0.4683 0.3425 0.4701 0.3530 0.5030 0.3760 0.1258 0.1171 0.1270 0.1233 0.0054 100.000 4.566 1.18 10 0.3697 0.3500 0.3727 0.3552 0.3588 0.3361 0.0197 0.0175 0.0227 0.0200 0.0026 12.662 2.206
3 0.4023 0.3600 0.3855 0.3456 0.3888 0.3451 0.0423 0.0399 0.0437 0.0420 0.0019 31.256 1.624 1 0.4092 0.3424 0.4369 0.3716 0.4178 0.3458 0.0668 0.0653 0.0720 0.0680 0.0035 53.288 2.972 0.3 0.4530 0.3478 0.4775 0.3636 0.4516 0.3454 0.1052 0.1139 0.1062 0.1084 0.0048 87.435 4.024
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3633 0.3622 0.3700 0.3699 0.3639 0.3647 0.0011 0.0001 -0.0008 0.0001 0.0010
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SP刺激 CNT 0.5194 0.3589 0.4883 0.3432 0.5243 0.3700 0.1605 0.1451 0.1543 0.1533 0.0077 100.000 5.059 0.73 10 0.3537 0.3495 0.3740 0.3674 0.3786 0.3705 0.0042 0.0066 0.0081 0.0063 0.0020 4.026 1.284
3 0.3994 0.3596 0.4072 0.3680 0.3944 0.3631 0.0398 0.0392 0.0313 0.0368 0.0047 23.917 3.097 1 0.4193 0.3545 0.4301 0.3620 0.4414 0.3646 0.0648 0.0681 0.0768 0.0699 0.0062 45.550 4.047 0.3 0.4662 0.3628 0.4594 0.3645 0.4576 0.3649 0.1034 0.0949 0.0927 0.0970 0.0057 63.243 3.689
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3315 0.3312 0.3400 0.3401 0.3390 0.3397 0.0003 -0.0001 -0.0007 -0.0002 0.0005
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SP刺激 CNT 0.4797 0.3401 0.4951 0.3555 0.5024 0.3492 0.1396 0.1396 0.1532 0.1441 0.0079 100.000 5.441 1.14 10 0.3567 0.3394 0.3627 0.3454 0.3627 0.3492 0.0173 0.0154 0.0135 0.0154 0.0019 10.788 1.317
3 0.3612 0.3295 0.3627 0.3310 0.3756 0.3422 0.0517 0.0428 0.0434 0.0460 0.0050 31.970 3.447 1 0.4101 0.3372 0.4146 0.3417 0.4287 0.3446 0.0729 0.0693 0.0841 0.0754 0.0077 52.391 5.349 0.3 0.4626 0.3352 0.4719 0.3445 0.4611 0.3449 0.1274 0.1095 0.1162 0.1177 0.0090 81.682 6.267 compound 1のSP 10μM刺激の細胞内Ca2+濃度上昇阻害IC50値は異なる実験3回の平均として算出
平均値 標準偏差値
IC50値 1.0 μM 0.2
Δratio
1 2 3
Δratio
1 2 3
10 μM SP刺激＋
compound ２ (μM )
Δratio
1 2 3
Δratio
1 2 3
Δratio
1 2 3
誘導比 (%) 誘導比
(%) 誘導比
(%)
10 μM SP刺激＋
compound ２ (μM )
Δratio
1 2 3
10 μM SP刺激＋
compound ２ (μM )
~ 92 ~
Table 2の基となるデータ（その3）
A, ペプチドもしくは溶媒添加後の最大ratio値 B, ペプチドもしくは溶媒添加前のratio値
ratio値とは340 nmの励起光で励起した際の510 nmの蛍光強度と，波長380 nmの励起光により励起した際の510 nmの蛍光強度の比の値。
Δratioとはサンプル添加後の最大変化ratio値（A-B）。
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3563 0.3583 0.3659 0.3650 0.3584 0.3424 -0.0020 0.0009 0.0160 0.0050 0.0097
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SPA刺激 CNT 0.6023 0.3610 0.5747 0.3545 0.5894 0.3554 0.2413 0.2202 0.234 0.2318 0.0107 100.000 4.723 3.85 10 0.4358 0.3529 0.4257 0.3498 0.4117 0.3520 0.0829 0.0759 0.0597 0.0728 0.0119 29.915 5.245
3 0.4961 0.3717 0.4832 0.3541 0.4813 0.3488 0.1244 0.1291 0.1325 0.1287 0.0041 54.525 1.793 1 0.5274 0.3629 0.5352 0.3568 0.4895 0.3467 0.1645 0.1784 0.1428 0.1619 0.0179 69.174 7.909 0.3 0.5411 0.3590 0.5282 0.3603 0.5307 0.3414 0.1821 0.1679 0.1893 0.1798 0.0109 77.050 4.800
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3504 0.3526 0.3444 0.3612 0.3518 0.3500 -0.0022 -0.0168 0.0018 -0.0057 0.0098
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SPA刺激 CNT 0.5476 0.3536 0.5582 0.3484 0.5307 0.3400 0.1940 0.2098 0.1907 0.1982 0.0102 100.000 5.007 3.18 10 0.3831 0.3418 0.3965 0.3435 0.3880 0.3500 0.0413 0.0530 0.0380 0.0441 0.0079 24.440 3.866
3 0.4539 0.352 0.4418 0.3417 0.4491 0.3578 0.1019 0.1001 0.0913 0.0978 0.0057 50.760 2.782 1 0.5291 0.3458 0.5145 0.3438 0.5313 0.3618 0.1833 0.1707 0.1695 0.1745 0.0076 88.393 3.749 0.3 0.5675 0.3525 0.5543 0.3408 0.5431 0.3517 0.2150 0.2135 0.1914 0.2066 0.0132 104.152 6.481
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3461 0.3466 0.3536 0.3544 0.3518 0.3532 -0.0005 -0.0008 -0.0014 -0.0009 0.0005
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SPA刺激 CNT 0.5970 0.3436 0.5828 0.32 0.6087 0.3474 0.2534 0.2628 0.2613 0.2592 0.0051 100.000 1.942 3.40 10 0.4282 0.3478 0.4315 0.338 0.4236 0.3378 0.0804 0.0935 0.0858 0.0866 0.0066 33.632 2.531
3 0.4715 0.3317 0.4515 0.3273 0.4753 0.3418 0.1398 0.1242 0.1335 0.1325 0.0078 51.295 3.018 1 0.5451 0.3358 0.5239 0.3417 0.5321 0.3353 0.2093 0.1822 0.1968 0.1961 0.0136 75.750 5.215 0.3 0.6041 0.3518 0.5638 0.3308 0.5763 0.3317 0.2523 0.2330 0.2446 0.2433 0.0097 93.899 3.736 compound 1のSPA 10μM刺激の細胞内Ca2+濃度上昇阻害IC50値は異なる実験3回の平均として算出
平均値 標準偏差値
IC50値 3.5 μM 0.3
Δratio
1 2 3
Δratio
1 2 3 誘導比
(%)
10 μM SPA刺激
＋compound 1 (μM )
Δratio
1 2 3
Δratio
1 2 3 誘導比
(%)
Δratio
1 2 3
10 μM SPA刺激
＋compound 1 (μM )
Δratio
1 2 3 誘導比
(%) 10 μM SPA刺激
＋compound 1 (μM )
~ 93 ~
Table 2の基となるデータ（その4）
A, ペプチドもしくは溶媒添加後の最大ratio値 B, ペプチドもしくは溶媒添加前のratio値
ratio値とは340 nmの励起光で励起した際の510 nmの蛍光強度と，波長380 nmの励起光により励起した際の510 nmの蛍光強度の比の値。
Δratioとはサンプル添加後の最大変化ratio値（A-B）。
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3703 0.3583 0.3671 0.365 0.3433 0.3424 0.0120 0.0021 0.0009 0.0050 0.0061
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SPA刺激 CNT 0.5317 0.3355 0.5433 0.3360 0.5575 0.3498 0.1962 0.2073 0.2077 0.2037 0.0065 100.000 3.284 4.77 10 0.4175 0.3441 0.4045 0.3402 0.4061 0.3527 0.0734 0.0643 0.0534 0.0637 0.0100 29.542 5.038
3 0.4606 0.3325 0.4604 0.3372 0.4893 0.3578 0.1281 0.1232 0.1315 0.1276 0.0042 61.693 2.099 1 0.5162 0.3373 0.4950 0.3465 0.5186 0.3517 0.1789 0.1485 0.1669 0.1648 0.0153 80.394 7.704 0.3 0.5155 0.3366 0.5145 0.3463 0.5339 0.3476 0.1789 0.1682 0.1863 0.1778 0.0091 86.952 4.579
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3633 0.3622 0.3700 0.3699 0.3639 0.3647 0.0011 0.0001 -0.0008 0.0001 0.0010
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SPA刺激 CNT 0.5647 0.3572 0.5803 0.3651 0.6143 0.3692 0.2075 0.2152 0.2451 0.2226 0.0199 100.000 8.928 3.89 10 0.4179 0.3594 0.4238 0.3640 0.4263 0.3755 0.0585 0.0598 0.0508 0.0564 0.0049 25.277 2.187
3 0.4781 0.3510 0.4988 0.3692 0.4893 0.3714 0.1271 0.1296 0.1179 0.1249 0.0062 56.068 2.770 1 0.5294 0.3547 0.5333 0.3654 0.5422 0.3719 0.1747 0.1679 0.1703 0.1710 0.0034 76.791 1.550 0.3 0.5461 0.3570 0.5757 0.3604 0.5576 0.3642 0.1891 0.2153 0.1934 0.1993 0.0141 89.512 6.316
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3315 0.3312 0.3400 0.3401 0.3390 0.3397 0.0003 -0.0001 -0.0007 -0.0002 0.0005
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM SPA刺激 CNT 0.6125 0.3347 0.6229 0.3451 0.6111 0.3500 0.2778 0.2778 0.2611 0.2722 0.0096 122.310 4.334 4.45 10 0.4053 0.3519 0.3972 0.3338 0.4023 0.3232 0.0534 0.0634 0.0791 0.0653 0.0130 29.293 5.823
3 0.4835 0.3480 0.4581 0.3396 0.4752 0.3345 0.1355 0.1185 0.1407 0.1316 0.0116 59.080 5.219 1 0.5655 0.3514 0.5543 0.3442 0.5392 0.3389 0.2141 0.2101 0.2003 0.2082 0.0071 93.512 3.192 0.3 0.5815 0.3505 0.5829 0.3519 0.5553 0.3555 0.2310 0.2310 0.1998 0.2206 0.0180 99.101 8.097 compound 2のSPA 10μM刺激の細胞内Ca2+濃度上昇阻害IC50値は異なる実験3回の平均として算出
平均値 標準偏差値
IC50値 4.4 μM 0.4
Δratio
1 2 3
Δratio
1 2 3
10 μM SPA刺激
＋compound ２ (μM )
Δratio
1 2 3
Δratio
1 2 3
Δratio
1 2 3
誘導比 (%)
誘導比 (%)
誘導比 (%)
10 μM SPA刺激
＋compound ２ (μM )
Δratio
1 2 3
10 μM SPA刺激
＋compound ２ (μM )
~ 94 ~
Table 2の基となるデータ（その5）
A, ペプチドもしくは溶媒添加後の最大ratio値 B, ペプチドもしくは溶媒添加前のratio値
ratio値とは340 nmの励起光で励起した際の510 nmの蛍光強度と，波長380 nmの励起光により励起した際の510 nmの蛍光強度の比の値。
Δratioとはサンプル添加後の最大変化ratio値（A-B）。
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3125 0.3127 0.3199 0.3211 0.3202 0.3198 -0.0002 -0.0012 0.0004 -0.0003 0.0008
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM PACAP刺激CNT 0.5968 0.3236 0.5642 0.3167 0.5776 0.3225 0.2732 0.2475 0.2551 0.2586 0.0132 100.000 5.099 1.16 10 0.3583 0.3142 0.3510 0.3106 0.3650 0.3158 0.0441 0.0404 0.0492 0.0446 0.0044 17.343 1.706
3 0.4109 0.3188 0.4030 0.3143 0.3987 0.3225 0.0921 0.0887 0.0762 0.0857 0.0084 33.213 3.234 1 0.4419 0.3152 0.4718 0.3236 0.4541 0.3219 0.1267 0.1482 0.1322 0.1357 0.0112 52.536 4.314 0.3 0.5140 0.3168 0.4940 0.3118 0.4945 0.3147 0.1972 0.1822 0.1798 0.1864 0.0094 72.116 3.642
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3342 0.3366 0.3319 0.3344 0.3321 0.3332 -0.0024 -0.0025 -0.0011 -0.0020 0.0008
1 2 3
A B A B A B 平均 標準偏差 標準偏差 IC50値
10 μM PACAP刺激CNT 0.5505 0.3307 0.5365 0.3294 0.5304 0.3313 0.2198 0.2071 0.1991 0.2087 0.0104 100.000 4.955 1.05 10 0.3741 0.3419 0.3694 0.3293 0.3683 0.3310 0.0322 0.0401 0.0373 0.0365 0.0040 18.291 1.901
3 0.3876 0.3351 0.3782 0.3365 0.3644 0.3246 0.0525 0.0417 0.0398 0.0447 0.0069 22.152 3.252 1 0.4409 0.3307 0.4357 0.3370 0.4504 0.3411 0.1102 0.0987 0.1093 0.1061 0.0064 51.297 3.036 0.3 0.5084 0.3296 0.4967 0.3325 0.4975 0.3399 0.1788 0.1642 0.1576 0.1669 0.0108 80.158 5.150
1 2 3
A B A B A B 平均 標準偏差
溶媒のみ 0.3352 0.3378 0.3385 0.3386 0.3301 0.3298 -0.0026 -0.0001 0.0003 -0.0008 0.0016
1 2 3
A B A B A B 平均 標準偏差CNT比(%)標準偏差 IC50値
10 μM PACAP刺激CNT 0.4954 0.3333 0.4944 0.3291 0.4770 0.3275 0.1621 0.1653 0.1495 0.1590 0.0084 100.000 5.228 1.32 10 0.3536 0.3315 0.3438 0.3223 0.3423 0.3292 0.0221 0.0215 0.0131 0.0189 0.0050 12.330 3.150
3 0.3886 0.3345 0.4033 0.3445 0.3896 0.3271 0.0541 0.0588 0.0625 0.0585 0.0042 37.096 2.635 1 0.4076 0.3287 0.4187 0.3222 0.4139 0.3316 0.0789 0.0965 0.0823 0.0859 0.0093 54.267 5.843 0.3 0.4725 0.3289 0.4667 0.3280 0.4685 0.3257 0.1436 0.1387 0.1428 0.1417 0.0026 89.193 1.645 compound 1のPACAP 10μM刺激の細胞内Ca2+濃度上昇阻害IC50値は異なる実験3回の平均として算出
平均値 標準偏差値
IC50値 1.2 μM 0.1
Δratio
1 2 3
Δratio
1 2 3 誘導比
(%)
10 μM PACAP刺 激＋compound 1
(μM )
Δratio
1 2 3
Δratio
1 2 3 誘導比
(%)
1 2 3
10 μM PACAP刺 激＋compound 1
(μM )
Δratio
1 2 3
10 μM PACAP刺 激＋compound 1
(μM )
Δratio